| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:CCT241736
CAS:1402709-93-6
Purity:>=98% Remarks:Reach out to us for more information about custom solutions.
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:CCT241736
CAS:1402709-93-6
Purity:98% Package:1G;10G;100G Remarks:CCT241736 is a potent and orally active and dual FLT3-Aurora inhibitor, which has IC50 values against FLT3, Aurora A and Aurora B of 0.035, 0.015 and 0.1 μM respectively. It also inhibits viability of
|
|
| | 3H-IMidazo[4,5-b]pyridine, 6-chloro-7-[4-[(4-chlorophenyl)Methyl]-1-piperazinyl]-2-(1,3-diMethyl-1H-pyrazol-4-yl)- Basic information |
| Product Name: | 3H-IMidazo[4,5-b]pyridine, 6-chloro-7-[4-[(4-chlorophenyl)Methyl]-1-piperazinyl]-2-(1,3-diMethyl-1H-pyrazol-4-yl)- | | Synonyms: | 3H-IMidazo[4,5-b]pyridine, 6-chloro-7-[4-[(4-chlorophenyl)Methyl]-1-piperazinyl]-2-(1,3-diMethyl-1H-pyrazol-4-yl)-;6-chloro-7-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]-2-(1,3-dimethylpyrazol-4-yl)-1H-imidazo[4,5-b]pyridine;CCT241736;CCT241736;CCT-241736;CCT 241736;CS-2683;6-Chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-1H-imidazo[4,5-b]pyridine;CCT 241736,Fms like tyrosine kinase 3,CCT241736,CD135,Inhibitor,FLT3,CCT-241736,Aurora Kinase,Cluster of differentiation antigen 135,inhibit;1-[6-chloro-2-(1,3-dimethyl-1H-pyrazol-4-yl)-1H-imidazo[4,5-b]pyridin-7-yl]-4-[(4-chlorophenyl)methyl]piperazine | | CAS: | 1402709-93-6 | | MF: | C22H23Cl2N7 | | MW: | 456.37 | | EINECS: | | | Product Categories: | API | | Mol File: | 1402709-93-6.mol | ![3H-IMidazo[4,5-b]pyridine, 6-chloro-7-[4-[(4-chlorophenyl)Methyl]-1-piperazinyl]-2-(1,3-diMethyl-1H-pyrazol-4-yl)- Structure](CAS/20150408/GIF/1402709-93-6.gif) |
| | 3H-IMidazo[4,5-b]pyridine, 6-chloro-7-[4-[(4-chlorophenyl)Methyl]-1-piperazinyl]-2-(1,3-diMethyl-1H-pyrazol-4-yl)- Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO:75.0(Max Conc. mg/mL);164.34(Max Conc. mM) | | form | A crystalline solid | | color | White to off-white |
| | 3H-IMidazo[4,5-b]pyridine, 6-chloro-7-[4-[(4-chlorophenyl)Methyl]-1-piperazinyl]-2-(1,3-diMethyl-1H-pyrazol-4-yl)- Usage And Synthesis |
| Uses | CCT241736 is a potent and orally bioavailable dual FLT3 and Aurora kinase inhibitor, which inhibits Aurora kinases (Aurora-A Kd, 7.5 nM, IC50, 38 nM; Aurora-B Kd, 48 nM), FLT3 kinase (Kd, 6.2 nM), and FLT3 mutants including FLT3-ITD (Kd, 38 nM) and FLT3(D835Y) (Kd, 14 nM). | | in vivo | CCT241736 (50, 100 mg/kg, b.i.d, p.o.) dose-dependently suppresses the growth of MV4-11 human tumor xenografts, and completely abolishes the tumors at 100 mg/kg via p.o. administration twice a day[1]. | | IC 50 | Aurora-A: 38 nM (IC50); Aurora-A: 7.5 nM (Kd); Aurora-B: 48 nM (Kd); FLT3(K663Q): 5.1 nM (Kd); FLT3: 6.2 nM (Kd); FLT3(D835H): 11 nM (Kd); FLT3(D835Y): 14 nM (Kd); FLT3(N841I): 16 nM (Kd); FLT3-ITD: 38 nM (Kd); FLT3(R834Q): 110 nM (Kd) | | References | [1] Bavetsias V, et al. Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia. J Med Chem. 2012 Oct 25;55(20):8721-34. DOI:10.1021/jm300952s |
| | 3H-IMidazo[4,5-b]pyridine, 6-chloro-7-[4-[(4-chlorophenyl)Methyl]-1-piperazinyl]-2-(1,3-diMethyl-1H-pyrazol-4-yl)- Preparation Products And Raw materials |
|